Measuring malaria drug efficacy and transmission intensity

Lancet

Volumn 368, Issue 9529, 2006, Pages 10-12

  Kachur, S Patrick ^a   Slutsker, Laurence ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLONE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISIN; CHLOROQUINE; FANSIDAR; FOLIC ACID ANTAGONIST; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; GENE MUTATION; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMAN; INOCULATION; MALARIA; MOSQUITO; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SUPERINFECTION; UGANDA;

EID: 33745395155     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68945-9     Document Type: Note

References (4)

1. Francis D., Nsobya S., Talisuna A., et al. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 193 (2006) 978-986
2. WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (2003). http://mosquito.who.int/cmc_upload/0/000/07/017/ProtocolWHO.pdf (accessed June 16, 2006)
3. Bloland P., Kachur S., and Williams H. Trends in antimalarial drug deployment in sub-Saharan Africa. J Exp Biol 206 (2003) 3761-3769
4. Drakeley C., Corran P., Coleman P., et al. Estimating medium-and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci USA 102 (2005) 5108-5113